Philippine Daily Inquirer19d
World’s first anti-depression nasal spray receives FDA approval
The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical company Johnson & Johnson created the spray from esketamine, a more ...
Hosted on MSN27d
FDA approves Johnson & Johnson’s nasal spray for depression as stand-alone treatment
The Food and Drug Administration approved Johnson & Johnson's nasal spray to be used alone in adults with a major depressive disorder that is difficult to treat, as sales of the drug grow.
WebMD27d
What to Know About the New Nasal Spray for Tough Depression
Jan. 27, 2025 – After years of limited options, people with hard-to-treat depression finally have a new standalone treatment. The FDA’s latest approval of the nasal spray Spravato (esketamine ...
Renal & Urology News27d
FDA Approves Spravato Nasal Spray for Treatment-Resistant Depression
CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least 2 oral antidepressants, according to a news release issued by Johnson & Johnson.
AZFamily23d
Ketamine-derived nasal spray treating Phoenix patients with severe depression
Spravato is a ketamine-derived nasal spray that is FDA-approved for treatment-resistant depression. The Johnson & Johnson drug has been on the market since 2019, but could only be prescribed ...
Medical News Today27d
FDA-approved nasal spray for severe depression can lead to remission
Share on Pinterest The FDA has approved an esketamine nasal spray for the treatment of ... compared to 7.6% of participants taking the placebo. “When Johnson & Johnson started researching ...
AOL27d
FDA-approved nasal spray for severe depression can lead to remission
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the ... 7.6% of participants taking the placebo. “When Johnson & Johnson started researching Spravato ...
Class action targets ‘ineffective’ phenylephrine-based cold medicines
A class action has been filed claiming a pharmaceutical giant sold and marketed in New Zealand cold medicines that did not ...
A Bitter Pill To Swallow: Class Action Targets Sudafed And Codral’s Ineffective Ingredient
Phenylephrine is a commonly used ingredient in cold and flu medications as a nasal and sinus decongestant. It is present in several on-the-shelf cold and flu medications in New Zealand, including ...
BioSpace6d
Psychedelics Space Regroups as RFK Jr. Signals Support
After the rejection of Lykos Therapeutics’ MDMA-based PTSD treatment tempered excitement for psychedelic therapeutics, a ...
Class action targets ‘ineffective’ cold medicines
Australia-based JGA Saddler has filed a class action lawsuit against Johnson & Johnson NZ over its phenylephrine-based cold ...
FOX 40 WICZ TV3d
U.S. Nasal Spray Market Expanding Rapidly | Demand, Trends & Key Growth Factors: Neurelis, Johnson & Johnson Services
The global U.S. Nasal Spray Market is expected to grow at 6.9% CAGR from 2025 to 2032. The latest Research report published by CMI with the title "An Increase in Demand and Opportunities for ...